Vireo GrowthFRA:K95 -5.39%44 Market Cap is €434.3 Mil as of Jun. 25, 2026. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Vireo Growth ranks better than 62.66% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vireo Growth's share price for the quarter that ended in Mar. 2026 was €9. Vireo Growth's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 36.0 Mil. Therefore, Vireo Growth's market cap for the quarter that ended in Mar. 2026 was €324.1 Mil.
Vireo Growth's quarterly market cap
increased
from Sep. 2025 (€455.9 Mil) to Dec. 2025 (€486.2 Mil) but then
declined
from Dec. 2025 (€486.2 Mil) to Mar. 2026 (€324.1 Mil).
Vireo Growth's annual market cap
increased
from Dec. 2023 (€26.9 Mil) to Dec. 2024 (€184.9 Mil) and
increased
from Dec. 2024 (€184.9 Mil) to Dec. 2025 (€486.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vireo Growth's Enterprise Value for Today is €680.6 Mil.
Vireo Growth (FRA:K95) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vireo Growth Market Cap Related Terms
Vireo Growth Market Cap Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Market Cap distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vireo Growth's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a Market Cap of €434.3 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #382 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Vireo Growth's Market Cap too high?
Vireo Growth's current Market Cap is €434.3 Mil. Based on the distribution chart, Vireo Growth ranks #382 out of 1023 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #382 out of 1023 companies for Market Cap. This puts Vireo Growth in the upper half of its industry. The industry median Market Cap is 206.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Market Cap is €434.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Market Cap is €434.3 Mil. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Market Cap is €434.3 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Market Cap: €434.3 Mil
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
